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Introduction
Hypercholesterolaemia is a risk factor of cardiovascular diseases
and is therefore a major target for primary and secondary preven-
tion.1,2 Maintaining a healthy diet and lifestyle reduces cardiovascu-
lar risk.3 ‘Functional foods’ supplemented with phytosterols are
advertised for the management of hypercholesterolaemia and
have become a widely used non-prescription approach to lower
plasma cholesterol levels. It is estimated that in 2005 worldwide
3 billion US-dollars were spent on various functional foods that
have regulator-approved health claims for the management of
elevated cholesterol levels.4
In September 2000, the US Food and Drug Administration (FDA)
issued an interim final rule allowing a health claim for reducing
the risk of coronary heart disease for foods that contain phytos-
terols and are low in saturated fat and cholesterol.5 In fact, this
was only the 12th time the FDA has authorized a health claim.
The National Cholesterol Education Program Expert Panel (NCEP
ATP III) recommends since 2001 phytosterol enriched functional
foods as part of an optimal dietetic prevention strategy in
primary and secondary prevention of cardiovascular diseases.6
The American Heart Association (AHA) has followed and sees
phytosterols ‘as a therapeutic option . . . for individuals with elev-
ated cholesterol levels’.3 Since then other well-esteemed societies
such as the Spanish Cardiology Society,7 the Association of Clinical and
Public Health Nutritionists in Finland,8 and the National Heart Foun-
dation in Australia,9 to name only a few, have identified phytosterols
as an important additional dietary option in the management of
hypercholesterolaemia. However, recently released guidelines are
more critical of food supplementation with phytosterols and
draw attention to significant safety issues.10,11
Phytosterols and cholesterol
absorption
‘Phytosterols’ are natural constituents of plants and are part of the
broad group of isoprenoides. In plant cells, they contribute to the
regulation of the fluidity and permeability of cell membranes, are
substrates for the synthesis of numerous secondary plant metab-
olites and act as biogenic precursors of compounds involved in
growth.12 Phytosterols are structurally related to cholesterol.
They are non-nutritive compounds whose chemical structure
differs from that of cholesterol only by minor modifications. Sitos-
terol and campesterol are the most frequent plant sterols and con-
stitute about 60% and 35%, respectively, of plant sterols in food.
They differ from cholesterol in the structure of their side chain
by a methyl or ethyl group at C-24. Plant stanols, on the other
hand, are the saturated form of plant sterols, meaning they have
no double bond in the sterol ring. Saturation of sitosterol, the
most commonly occurring plant sterol, gives rise to sitostanol; sat-
uration of campesterol gives rise to campestanol. See also Figure 1.
Estimates for intestinal absorption range from 0.4 to 5% for plant
sterols and from 0.02 to 0.3% for their saturated counterparts.13,14
Consequently, plant stanol concentrations in serum are much
lower than plant sterol concentrations. Phytosterols are abundant
in fat-laden vegetables and vegetable products, such as vegetables
oils and olive oil, but also in fruits and nuts. Although cholesterol
and phytosterols are structurally similar, they are metabolized dif-
ferently. In contrast to cholesterol, phytosterols are not syn-
thesized in the body and are solely of dietary origin. The normal
Western-type diet contains about 200–500 mg cholesterol,
200–400 mg plant sterols, and about 50 mg of plant stanols. In
order to be absorbed, cholesterol and phytosterols are taken up
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in micelles. Sterol-laden micelles interact with the intestinal brush
layer, enabling absorption in entrocytes. Phytosterols competitively
inhibit intestinal absorption of cholesterol. The exact molecular
mechanisms involved are not completely understood; however, it
is clear that both cholesterol and phytosterols require the
Niemann-Pick C1 Like 1 protein (NCP1L1) to obtain entry in
enterocytes. In enterocytes, cholesterol is esterified via the
enzyme acetyl-coenzyme A acetyltransferase 2 (ACAT2), packed
into chylomycrons, and drained into the lymph system via the
basolateral membrane. Non-esterified cholesterol and phytoster-
ols are pumped back into the intestinal lumen via the ATP proteins
ABCG5 and ABCG8. These complex mechanisms are responsible
for the assimilation of about 50% of cholesterol, but less than 5% of
plant sterols and even less than 0.5% of plant stanols. The major
part of assimilated phytosterols is directly eliminated via the liver
and the biliary system so that, in the end in healthy individuals,
less than 1% is retained.15
Phytosterols in nutraceuticals
The plant sterol sitosterol was first described as a therapeutic
agent for hypercholesterolaemia in 1951.16 In the late 1950s, Eli
Lilly Company introduced the first plant sterol product, ‘Cytellin’,
as a cholesterol-lowering pharmaceutical.17 Due to its low water
solubility and the resulting low bioavailability, a daily intake of
18 g of sitosterol was needed to achieve a reduction in serum
cholesterol levels. The product was unmarketable as a pharma-
ceutical agent and production was stopped. A resurgence of inter-
est in phytosterol effects came after it could be demonstrated that
phytosterols were active when incorporated into the diet as
spreads. In the beginning of the 90s, researchers succeeded by
the esterification of phytosterols in developing a process which
considerably improved the water solubility of phytosterols.18
This process made it possible to greatly expand the market for
phytosterols as dietary supplements, leading to a rapidly growing
world-wide market for functional-foods.19,20 At present in the
EU, in addition to spreads, there are numerous other foods
approved for the market to which phytosterols have been
added, for example, salad dressing; milk, soy, yoghurt, cheesy pro-
ducts; soy and fruit drinks, even sausages and breads. Above all,
combined consumption of these new types of products can lead
to a cumulative intake of very high concentrations especially of
plant sterols, which can affect the absorption of cartenoids and
fat-soluble vitamin.21 This can, for example, constitute a hazard
to children, pregnant and breastfeeding women. A labelling,
therefore, advises these individuals to avoid consuming these
products. Furthermore, it has been suggested as a precaution
that phytosterol intake should not exceed 3 g per day.22
Phytosterols and cardiovascular
risk
Meta-analyses of more than 40 clinical studies indicate that phytos-
terols taken as dietary supplements can induce a reduction of
LDL-cholesterol up to 15%23,24 (Figure 2). However, ingestion of
Figure 1 Chemical structure of cholesterol, sitosterol (plant
sterol), and sitostanol (plant stanol). Both plant sterols and plant
stanols differ from cholesterol only in the side chain attached to
the sterol ring. Plant stanols are saturated plant sterols without a
double bond in the sterol ring. Due to their saturation status,
plant stanols are less effectively absorbed. Esterified plant sterols
and plant stanols are supplemented in ‘nutraceuticals’ to reduce
serum cholesterol levels (modified from ref. 14).
Figure 2 Plant sterols reduce serum cholesterol levels. Total cholesterol and LDL-cholesterol dependent on diet (modified from ref. 23).
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more than 3 g/day does not lead to any further lowering of choles-
terol levels. Of note, a diet supplementation with plant stanol
esters reduces not only serum cholesterol levels, but also serum
plant sterol concentrations.25 The effectiveness of cholesterol-
lowering products does not only depend on the amount of
dietary phytosterols, but also on genetically determined differences
in sterol metabolism. Thus, for example, Apo E-4 (apolipoprotein
E-4) homozygote patients on a diet supplementation with phytos-
terols show a more significant reduction in LDL-cholesterol due to
their increased cholesterol absorption capacity.26 However, with
this genotype lowered cholesterol levels are associated with mark-
edly increased plant sterol serum concentrations. The significance
of increased plant sterol levels, however, is not clear.
Speculations that plant sterols may represent a cardiovascular
risk factor were first brought up after the understanding of the
autosomal-recessively inherited disease of sitosterolaemia.27 Elev-
ated plant sterol concentrations, xanthomatosis, and premature,
frequently lethal atherosclerosis in young subjects are the most
striking features regarding patients with homozygous sitostero-
laemia. Additional findings are thrombocytopenia, abnormally
deformed erythrocytes with membranous incorporation of phy-
tosterols, extending to haemolytic crisis, arthralgias, and increased
liver enzyme levels. The reason for this are mutations of the gene
locus of the ABCG5 and ABCG8 co-transporters, resulting in
increased absorption and reduced biliary elimination of all
sterols.28 In contrast to healthy subjects who have a plant sterol
plasma concentration lower than 1 mg/dL, patients who suffer
from this rare autosomal-recessive, inherited disease, have
plasma concentrations of between 12 and 50 mg/dL. On the
other hand, cholesterol does not need to be excessively high.
The fact that patients with this disease present with an aggressive
vascular disease process despite nearly normal cholesterol levels
brought up the question whether phytosterols have a particularly
atherogenous potential. As sterol analyses of xanthomas of such
patients indicate that phytosterols only contain a small portion
of sterols and that the major portion consists of free and esterified
cholesterol, it is currently suggested that plant sterols can promote
the incorporation of cholesterol in tissue.27–29 This speculation is
in agreement with the findings of a recently published study in
which the NPC1L1 inhibitor ezetimibe led to a regression in
xanthomatosis in parallel to lowering of both cholesterol and
plant sterol levels.30
Even though many different clinical trials have clearly demon-
strated that phytosterols reduce LDL-cholesterol, it is unclear
whether phytosterols have a positive effect on cardiovascular
disease.24 Until now, there are no data on the effect of phytosterol
consumption on the development of cardiovascular diseases avail-
able.32 In fact, there is evidence that elevated levels of plant sterols
are associated with an increased cardiovascular risk. Glueck et al.33
were the first to report that elevated plant sterols might be a risk
factor for coronary heart disease. In a study with 595 hypercholes-
terolaemic patients, they found that slightly elevated plasma levels
of plant sterols were a heritable marker for an increased cardiovas-
cular risk. Salen et al.31 reported that in homozygotes of sitoster-
olaemia cholesterol accounted for over 80% of plasma, tissue, and
atheroma sterol. In seven subjects in a Glueck study, serum choles-
terol was 7.09 mmol/L, whereas the concentration of campesterol,
stigmasterol, and sitosterol combined was only 43.86mmol/L.34
Therefore, it can be speculated that a slight excess of serum
plant sterol levels may increase sterol deposition in cardiovascular
tissue. This hypothesis is supported by the study of Rajaratnam
et al.35 who found that in postmenopausal women, plant sterols
were independently associated with coronary heart disease in a
multivariate analysis. These findings were confirmed by Sutherland
and his team in a study involving both sexes over all age groups.36
Sudhop et al.37 analysed the relation of a positive family history of
coronary heart disease to serum plant sterol concentrations in
CAD patients without lipid-modifying medications. There were
no differences in levels of serum cholesterol, cholesterol precur-
sors, and lipoproteins. The serum campesterol level in the
control group was 0.38 mg/dL compared to 0.50 mg/dL in those
patients with a positive family history. Given that the level of
plant sterols was small compared with cholesterol (0.16 vs.
0.21%), the effect inducing a negative cardiovascular outcome in
this study is indeed very potent. Similar findings have been
reported for patients on statin treatment. The Scandinavian Sim-
vastatin Survey Study (4S study) also identified a subpopulation
of coronary artery disease patients with low endogenous synthesis
of cholesterol and high absorption of cholesterol and plant sterols.
The subjects of this subpopulation had the highest levels of plant
sterols and the highest risk of recurrent coronary events despite
lower levels of serum cholesterol due to simvastatin ingestion.38
Larger epidemiological studies reported similar data. Results of
the PROCAM-study showed that patients afflicted with myocardial
infarction or sudden cardiac death had increased plant sterol con-
centrations.39 Upper normal levels of plant sterols were associated
with a three-fold increase of risk for coronary events among
men in the highest tertile of coronary risk according to the
PROCAM-algorithm (Figure 3). Similar data are available for the
plant sterol campesterol from the MONICA/KORA-study. In this pro-
spective study, campesterol correlated directly with the incidence
of acute myocardial infarction.40 Current experimental findings
Figure 3 Plant sterols increase cardiac risk. PROCAM-score
for the 10 year risk to develop coronary heart disease
(n ¼ 477) according to subgroups with increasing risk
(PROCAM-score ,10, 10–20, .20). Slightly elevated sitosterol
levels are associated with increased cardiac risk. *P, 0.05 low
sitosterol (,0.21 mg/dL) vs. elevated sitosterol (.0.21 mg/dL)
(modified from ref. 39).
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from our own research group show that a diet supplementation
with plant sterol esters that is equivalent to a commercially
available spread induces endothelial dysfunction and leads to an
increase of ischaemic stroke size in wild-type mice.29 In
atherosclerotic-prone apoE2/2 mice, we compared the effects
of a diet supplementation with plant sterol esters with equal
cholesterol lowering by a second intervention in relation to ather-
osclerotic lesion formation. Ezetimibe was chosen as a comparator,
because similar to plant sterols, this two-azetidione is an inhibitor
of intestinal cholesterol absorption and lowers plasma cholesterol
levels. As expected, the substantial lipid-lowering by both
treatment principles reduced atherosclerotic lesion formation.
However, despite equal plasma cholesterol levels, plant sterol
ester supplementation was associated with twice the amount
of plaque formation compared with ezetimibe. Thus, we found a
positive correlation between sterol concentrations and the
extent of atherosclerotic lesions.29 Moreover, in a clinical study,
we demonstrated that patients who were consuming plant sterol
ester enriched margarine had increased concentrations of plant
sterols in cardiovascular tissue.29 Further mechanistic data
suggest that vascular deposits of sterols, when compared with
cholesterol, result in increased oxidation and release of oxygen
radicals.41 On the other hand, previous animal and in vitro experi-
ments have shown that plant sterols have positive effects that
directly inhibit tumour growth, including the slowing of cell cycle
progression, the induction of apoptosis, and the inhibition of
tumour metastasis, suggesting that these compounds have anti-
cancer properties.42 However, the induction of apoptosis is not
limited to tumour cells, but extends also to vascular cells. Recent
in vitro experiments demonstrated that the plant sterol sitosterol
exerts a strong cytotoxic propensity inducing apoptosis in human
endothelial cells, revealing detrimental effects on the vasculature.43
In fact, the first experimental study reporting negative cardiovascular
effects dates back to the year 2000. Ratnayake et al.44 reported that
increased serum levels of plant sterols increase rigidity of erythro-
cytes and shorten the life span of stroke-prone spontaneously
hypertensive (SHRSP) rats. These findings were the reason for
Health Canada, the federal department responsible for helping
Canadians maintain and improve their health, to raise significant
safety issues and not to allow functional foods enriched with plant
sterol esters to be sold in Canada.45
Phytosterols as adjunct to
over-the-counter drugs
Just recently, a plant sterol–aspirin combination product has been
launched in the USA, despite the fact that the FDA has written
warnings to companies marketing the combination of drugs with
dietary supplements in the past.46,47 This ‘analgetic phytosterol
supplement’ combines 81 mg aspirin and 400 mg of plant sterols
and carries both over-the-counter (OTC) drug and dietary sup-
plement labelling and claims. The American Herbal Products
Association (AHPA), however, took issue with this kind of market-
ing because it implied both active ingredients have been submitted
to pharma-level testing when in fact only the OTC drug ingredients
had been tested. According to the AHPA, this would be potentially
deceptive for consumers and would constitute a change in FDA
policies. At present, this issue highlights a legal grey area that
requires further refinement.48
Do current guidelines for
therapeutic lifestyle changes have
to be reconsidered?
Since the introduction on the market of the first phytosterol
enriched margarine, no cases with negative health effects have
been reported. However, controlled studies are only available
for an observational period of up to 1 year, for which the
number of participants was low and the special effects of plant
sterols were not studied separately, so that the possible
pro-atherosclerotic effects due to long-term consumption could
not be detected in these studies.19,20,23,24,49 In contrast to func-
tional foods enriched with saturated, less absorbable plant stanol
esters (which reduce not only serum cholesterol, but also plant
sterol levels), a diet supplementation with plant sterol esters has
proven to lead to a significant increase in plant sterol levels.20,50
Functional foods are marketed directly to consumers. In com-
parison to drugs, food supplements are subject to much ‘weaker’
authorization and control requirements, but this does not
exclude the possibility that they might be hazardous.
Due to the lack of evidence regarding clinical events and the
potential for negative side-effects, the ‘health claim’ of the US
Food and Drug Administration, the NCEP ATP III guidelines, and
the current diet and lifestyle recommendations of the American
Heart Association should be re-evaluated. The German Drug
Commission (Arzneimittelkommission der Deutschen A¨rzteschaft)
has stated in January 2004 that because of unclear safety data and
lacking evidence of effectiveness, the general use of such products
was not to be recommended.10 Similarly, the recently revised
guidelines for primary and secondary prevention of cardiovascular
diseases of the National Health System (NHS) call for randomized
controlled trials testing relevant clinical endpoints.11 As long as
results of such trials are pending, recommendation of functional
foods or drugs supplemented with plant sterol esters to reduce
serum cholesterol concentrations will be a matter of controversial
debate.
Summary points
Currently there are no data available indicating that functional
foods supplemented with plant sterol esters reduce cardiovascular
events.
Findings in patients with the hereditary disease of sitosterolae-
mia, data from epidemiological studies, as well as recently pub-
lished in vitro and in vivo data suggest that plant sterols potentially
induce negative cardiovascular effects.
Prospective clinical studies testing relevant clinical endpoints are
needed, before a diet supplementation with plant sterol esters can
be recommended.
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